Kelli Bradbury, APRN
Nurse Practitioner · Topeka, KSNPI 1528159050
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi-aventis U.S. LLC accounts for 60.1% of it on its own, with 27 other manufacturers making up the rest. Among nurse practitioner clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 344 payments — averaging $57.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$12K
- Novo Nordisk$2K
- Corcept Therapeutics$632
- Xeris Pharmaceuticals, Inc.$624
- Amgen$533
- Ascensia Diabetes Care US Inc.$510
- plus $4K from 22 others
What the payments were for
- Speaking & faculty fees$8,67044%
- Travel & lodging$1,3457%
- Food & beverage$9,57449%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 56 | $11,815 |
| Novo Nordisk | 67 | $1,599 |
| Corcept Therapeutics | 25 | $632 |
| Xeris Pharmaceuticals, Inc. | 25 | $624 |
| Amgen(2 entities) | 7 | $533 |
| Ascensia Diabetes Care US Inc. | 9 | $510 |
| Insulet Corporation | 21 | $431 |
| Boehringer Ingelheim | 21 | $407 |
| Lilly USA, LLC | 19 | $378 |
| Abbott | 5 | $338 |
| Averitas Pharma Inc. | 16 | $332 |
| Dexcom, Inc. | 5 | $289 |
| GRT US Holding, Inc. | 15 | $275 |
| AstraZeneca | 12 | $244 |
| Bayer | 3 | $232 |
| AbbVie | 11 | $201 |
| Mannkind Corporation | 5 | $196 |
| Novartis | 5 | $160 |
| Medtronic | 2 | $98 |
| Esperion Therapeutics, Inc. | 1 | $93 |
| Tandem Diabetes Care, Inc. | 2 | $65 |
| Zealand Pharma US, Inc. | 4 | $50 |
| Pfizer | 2 | $36 |
| Antares Pharma, Inc. | 2 | $36 |
| Sequel Med Tech, LLC | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$6,322
- SOLIQUA 100/33$2,291
- TOUJEO$792
- TEPEZZA$347
- Wegovy$246
- Korlym$233
- Qutenza$123
- EVERSENSE E3 SMART TRANSMITTER KIT$122
- GVOKE HYPOPEN$122
- Saxenda$117
- FreeStyle Libre$113
- Kerendia$107
- Ozempic$106
How this compares
$19,648 in reported general payments places this provider in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 253 | $330,955 |
| JardianceEmpagliflozin | 133 | $117,427 |
| TrulicityDulaglutide | 73 | $94,034 |
| FarxigaDapagliflozin Propanediol | 85 | $90,157 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 53 | $78,466 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 98 | $76,966 |
| Tresiba Flextouch U-100Insulin Degludec | 75 | $74,454 |
| MounjaroTirzepatide | 64 | $69,208 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 54 | $50,925 |
| Novolog FlexpenInsulin Aspart | 100 | $39,403 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 113 | $38,366 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $37,643 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $36,524 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $25,461 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 126 | $21,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,599 | $341,633286 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $378 | $168,126167 claims |
| Boehringer IngelheimJardiance, Tradjenta | $407 | $128,697149 claims |
| AstraZenecaFarxiga | $244 | $90,15785 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $11,815 | $25,46129 claims |
| AbbVieSynthroid | $201 | $8,64695 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Topeka
- Gary GrafTopeka$726K
- Shannon GreggTopeka$140K
- Laura WelbornTopeka$8K
- Alexandra HeerenTopeka$8K
- Amie WunderTopeka$8K
- Jayda RuppTopeka$7K
- Lora UtechTopeka$6K
- Anna ShortRoeland Park$215K
- Morteza RabiiOverland Park$88K
- Constance JacobWichita$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.